Sangamo Therapeutics (SGMOQ) EBT (2010 - 2025)

Sangamo Therapeutics' EBT history runs 16 years deep, the most recent figure standing at -$38.0 million for Q4 2025.

• On a quarterly basis, EBT fell 59.39% year-over-year to -$38.0 million in Q4 2025; TTM through Dec 2025 was -$123.5 million, a 25.88% decrease from a year earlier, with the FY2025 full-year figure at -$123.5 million, down 25.88% from the prior year.
• EBT eased to -$38.0 million in Q4 2025 per SGMOQ's latest filing, from -$35.1 million in the prior quarter.
• Across five years, EBT topped out at $21.3 million in Q1 2023 and bottomed at -$120.8 million in Q2 2023.
• The 5-year median for EBT is -$43.5 million (2022), against an average of -$42.7 million.
• Across the five-year window, EBT sank 3645.24% in 2021 and soared 148.56% in 2023, its largest moves.
• Year by year, EBT stood at -$37.6 million in 2021, then sank by 37.67% to -$51.7 million in 2022, then retreated by 17.12% to -$60.6 million in 2023, then soared by 60.67% to -$23.8 million in 2024, then sank by 59.39% to -$38.0 million in 2025.
• Per Business Quant, the three latest SGMOQ EBT figures stand at -$38.0 million (Q4 2025), -$35.1 million (Q3 2025), and -$20.0 million (Q2 2025).